TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Care
Description: Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
Study: NCT00795808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tds for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet tds for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Clomiphene
Description: 500mg tds + Ovulatory dose for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tds for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Ovulatory dose for 6 months
Study: NCT03632317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 30 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 3.0 mg/m\^2
Study: NCT00941057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
Description: Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)
Description: Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY 86-7660,levomefolate calcium
Description: Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
Study: NCT00302549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FK506
Description: FK506,0.1mg/kg/d
Study: NCT03716076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 50 mcg or 100 mcg bolus of carbetocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 50 mcg or 100 mcg bolus of carbetocin
Study: NCT01918826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Study: NCT03581487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT00690326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral change communication to promote physical activity
Description: treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral change communication to promote physical activity
Description: Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire
Study: NCT01479257

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.

Intervention type: DEVICE
Intervention: Accelerometer
Description: Small device worn on the hip for 7 consecutive days that measures physical activity.

Intervention type: DEVICE
Intervention: Smart Phone
Description: Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
Study: NCT03806842

Intervention type: DEVICE
Group type: OTHER
Intervention: Easytech group
Description: total shoulder replacement
Study: NCT01900665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT03139461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT-REFER Capacity-building Toolkit
Description: 1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls
Study: NCT04663074

Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS control
Description: Intravascular Control of the bridging stentgrafts during branched EVAR
Study: NCT01354431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
Study: NCT01595165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided subcostal TAP block
Description: Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound guided subcostal TAP block
Description: Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
Study: NCT02790333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional reloads
Description: Blue cartridge with3.0mm height staple was used for pancreatic stump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tri-Staple reloads
Description: Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
Study: NCT02595047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue/ organ prefabrication
Description: tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
Study: NCT04065191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Heart rate based high-intensity interval training
Study: NCT03101059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation - Continuous Positive Airway Pressure
Description: To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
Study: NCT02294318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthCall+Motivational Interviewing
Description: HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
Study: NCT03143972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Single drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Single drug administration
Study: NCT02147496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study: NCT02221271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study: NCT02240745

Intervention type: OTHER
Intervention: Stress-echocardiography
Description: Stress-echocardiography (incl dobutamin and atropin)
Study: NCT01975077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
Study: NCT02395653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
Study: NCT02521623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiMend® Acellular Dermal Matrix
Description: See arm description.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice™ Acellular Dermal Matrix
Description: See arm description.
Study: NCT02858687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Study: NCT02697630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
Study: NCT01540968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition & physical exercise
Description: Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
Study: NCT04213040

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum levels of Procalcitonin, C-reactive protein, lactate
Description: Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods.
Study: NCT01225367

Intervention type: DEVICE
Intervention: ultrasound doppler monitoring
Description: Regular noninvasive chest echo monitoring
Study: NCT02467829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increase in handle height
Description: Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increase in handle height
Description: Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
Study: NCT03499080

Intervention type: BEHAVIORAL
Intervention: Medication free treatment
Description: Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).

Intervention type: BEHAVIORAL
Intervention: Treatment as usual Myrvegen
Description: Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).

Intervention type: BEHAVIORAL
Intervention: Treatment as usual Åråsen
Description: Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
Study: NCT02776956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin group
Description: Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation

Intervention type: DRUG
Group type: OTHER
Intervention: non-atorvastatin group
Description: Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
Study: NCT02492087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
Study: NCT02759016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Standard of Care
Study: NCT02743195

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Polyphenol/prebiotic blend
Study: NCT02318134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT via a nasoduodenal tube with fresh bacteria from healthy donor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline via a nasoduodenal tube.
Study: NCT00031694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study: NCT01925339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test (immediate restoration)
Description: Test (immediate restoration)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control: delayed restoration
Description: Control: delayed restoration
Study: NCT02619786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled colistin
Description: 75 mg of colistin activity, inhaled per dose, every 12 hours
Study: NCT03240978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
Study: NCT04537403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)
Description: Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
Study: NCT04356118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Endostatin
Description: endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathcal methotrexate
Description: Intrathecal chemotherapy specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted drugs for non-small cell lung cancer
Description: EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
Study: NCT00841906

Intervention type: DEVICE
Group type: OTHER
Intervention: Alice PDx with only written instructions
Description: Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: Alice PDx with written and verbal instructions
Description: Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
Study: NCT01193738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic compression of Pterygopalatine node
Description: osteopathic compression of Pterygopalatine node

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: osteopathic compression of Pterygopalatine node
Description: osteopathic compression of Pterygopalatine node
Study: NCT03826498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP CB-MNC injection
Description: CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: The standard therapy can include drugs, special psychology training etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: The standard therapy can include drugs, special psychology training etc.
Study: NCT00683982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 15mg/Kg/day twice day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic mix preparation
Description: Probiotic preparation 1 gram twice a day for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral hydration solutions
Description: Oral hydration solutions as needed
Study: NCT02429141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided periarterial techique
Description: The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided multi-injection technique
Description: The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve